Europe — EMA
Ordspono (Odronextamab)
Odronextamab, the active ingredient in Ordspono, is a bispecific T‑cell engager presented as a solution for intravenous use in the treatment of certain hematologic malignancies.
Request sourcing
What is Odronextamab?
Odronextamab, the active ingredient in Ordspono, is a bispecific T‑cell engager presented as a solution for intravenous use in the treatment of certain hematologic malignancies. It redirects immune cells to target malignant B‑cells in patients with relapsed or refractory disease.
GNH USA supplies Ordspono as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.
What is Odronextamab used for?
Ordspono is a bispecific antibody that targets the CD20‑positive B‑cell malignancy pathway.
- Relapsed/refractory large B‑cell lymphoma: provides an option for patients who have exhausted standard therapies. - Relapsed/refractory follicular lymphoma: aims to induce durable responses in heavily pre‑treated individuals. - Relent‑or ...
What are the side effects of Odronextamab?
Common ...
What precautions apply to Odronextamab?
...
What does Odronextamab interact with?
...
